Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease
Author:
- 1 December 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 17 (12) , S31-S38
Abstract
Although the features of diabetic cardiomyopathy, atherosclerosis, and nephropathy have been clinically characterized, the pathogenesis and the mechanisms underlying the abnormalities in the diabetic heart and kidney are not fully understood. During the past several years, in an attempt to discover interventions for diabetes-related complications, researchers have refocused their attention from the hemodynamic aspects of the disease to the biochemical interactions of glucose and proteins. Diabetes is a disorder of chronic hyperglycemia, and glucose participates in diabetic complications such as atherosclerosis, cardiac dysfunction, and nephropathy. Chronic hyperglycemia accelerates the reaction between glucose and proteins and leads to the formation of advanced glycation end products (AGE), which form irreversible cross-links with many macromolecules such as collagen. In diabetes, these AGE accumulate in tissues at an accelerated rate. The development of the novel compound dimethyl-3-phenacylthiazolium chloride (alagebrium chloride), which chemically breaks AGE cross-links, led to several preclinical animal studies that showed an attenuation or reversal of disease processes of the heart and kidney. In diabetes, AGE not only structurally stiffen structural collagen backbones but also act as agonists to AGE receptors (RAGE) on various cell types, which stimulate the release of profibrotic growth factors, promote collagen deposition, increase inflammation, and ultimately lead to tissue fibrosis. In the heart, large vessels, and kidney, these reactions produce diastolic dysfunction, atherosclerosis, and renal fibrosis. Administration of the cross-link breaker alagebrium chloride in these diabetic animals attenuates these pathologic phenomena, restoring functionality to the heart, vasculature, and kidney.Keywords
This publication has 18 references indexed in Scilit:
- The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetesThe FASEB Journal, 2003
- An inhibitor of advanced glycation end product formation reducesN-(carboxymethyl)lysine accumulation in glomeruli of diabetic ratsAmerican Journal of Kidney Diseases, 2003
- Advanced glycation end products: A nephrologist's perspectiveAmerican Journal of Kidney Diseases, 2000
- Protein Crosslinking by the Maillard Reaction: Dicarbonyl-Derived Imidazolium Crosslinks in Aging and DiabetesArchives of Biochemistry and Biophysics, 1999
- Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproductsNature Medicine, 1998
- Increased Pentosidine, an Advanced Glycation End Product, in Plasma and Synovial Fluid from Patients with Rheumatoid Arthritis and Its Relation with Inflammatory MarkersBiochemical and Biophysical Research Communications, 1998
- Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatmentKidney International, 1996
- Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular diseaseDiabetes/Metabolism Research and Reviews, 1988
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988
- Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-LinkingScience, 1986